Platol

Cisplatin

Metastatic non-seminomatous germ cell carcinoma. Advanced stage, refractory ovarian & bladder carcinoma. Refractory head & neck squamous cell carcinoma.

Adult & childn Monotherapy 50-120 mg/m² single dose every 3-4 wk or 15-20 mg/m² daily for 5 days every 3-4 wk. Combination chemotherapy ≥20 mg/m² once every 2-3 wk. Cervical cancer 40 mg/m² wkly for 6 wk in combination w/ RT.

Hypersensitivity to cisplatin or other platinum compd. Dehydration, myelosuppression, preexisting hearing impairment, neuropathy. Combination w/ live vaccines including yellow fever vaccine, phenytoin in prophylaxis. Preexisting renal impairment. Lactation.

Hypersensitivity; inj site reactions. Ototoxicity, nephrotoxicity & neurotoxicity. Predisposed hyperuricaemia & hyperalbuminaemia; peripheral neuropathy; prior simultaneous cranial irradiation. Bone marrow depression; myelosuppression. Acute bacterial or viral infections. Determine & monitor renal, hepatic & haematopoiesis function & serum electrolytes prior to, during & after therapy. Ensure adequate hydration. Avoid contact w/ Al-containing IV sets, needles, catheters, syringes. Renal dysfunction. Women of childbearing potential should use effective contraception. Avoid use during pregnancy. Not to be used during lactation.

Bone marrow failure, thrombocytopenia, leukopenia, anaemia; hyponatraemia; hyperuricaemia. Sepsis; arrhythmia, bradycardia, tachycardia; inj site phlebitis; dyspnoea, pneumonia, resp failure.

Boosted myelosuppressive activity w/ myelosuppressives or radiation. Intensified nephrotoxicity occurrence w/ antihypertensives containing furosemide, hydralazine, diazoxide & propranolol. Potentiated renal toxic effects w/ cephalosporins, aminoglycosides, amphotericin B or contrast media. Potentially reduced renal elimination w/ cytostatic agents eg, bleomycin, MTX. Raynaud phenomenon w/ vinblastin. Renal toxicity & increased hearing loss w/ ifosfamide. Reduced lithium blood values w/ etoposide. Increased serum uric acid conc w/ allopurinol, colchicine, probenecid or sulfinpyrazone. Severe neurotoxic effects w/ docetaxel. Diminished effectiveness by chelating agents ie, penicillamine. Excessive immunosuppression w/ ciclosporin. Potentiated ototoxic effects w/ aminoglycosides, loop diuretics. Risk of fatal systemic vaccinal disease w/ yellow fever vaccine. Regularly check INR w/ oral anticoagulants. Masked ototoxicity symptoms w/ antihistamines, buclizine, cyclizine, loxapine, meclozine, phenothiazines, thioxanthenes or trimethobenzamides. Reduced absorption of phenytoin. Affected response time w/ pyroxidine + altretamine combination. Reduced clearance of paclitaxel.

Cytotoxic Chemotherapy

L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

B